Key result
Adding antiplatelets to rivaroxaban in AF is linked to increased bleeding but no stroke benefit.
Why the study?
The risks and benefits of rivaroxaban plus antiplatelet therapy remained to be evaluated in patients with non-valvular AF complicated by stable CAD, ischemic stroke, or PAD.
Does adding antiplatelet therapy to rivaroxaban reduce ischemic outcomes or increase bleeding in patients with non-valvular AF complicated by stable CAD, ischemic stroke, or PAD?
Cohort (n=2,030)
Yes
Does adding antiplatelet therapy to rivaroxaban reduce ischemic outcomes or increase bleeding in patients with non-valvular AF complicated by stable CAD, ischemic stroke, or PAD?
Adding antiplatelet therapy to rivaroxaban in patients with non-valvular atrial fibrillation and stable CAD or prior ischemic stroke does not improve ischemic outcomes but significantly increases the risk of bleeding.
Answers are grounded in this paper and cite their sources.
May increase bleeding without ischemic benefit in stable non-valvular AF; leaves open need for randomized confirmation before practice change.
AIM: In this subanalysis of the EXPAND study, we evaluated the risks and benefits of rivaroxaban plus antiplatelet therapy (APT) for patients with non-valvular atrial fibrillation (NVAF) complicated by stable coronary artery disease (CAD), ischemic stroke, or peripheral artery disease (PAD). METHODS: From the EXPAND study population (n=7,141), patients with NVAF complicated by stable CAD (n=886), ischemic stroke (n=1,231), or PAD (n=160) were included. Patients complicated by any of them were set as ALL (n=2,030). Patients were all treated with rivaroxaban (10 or 15 mg/day) with (+) or without (-) APT. Efficacy outcomes were symptomatic stroke+systemic embolism (SE), symptomatic stroke+SE+myocardial infarction+cardiovascular death, and all-cause death. Safety outcomes included major and any bleeding. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for differences between the APT(+) and APT(-) groups. RESULTS: There were no significant differences in the efficacy outcomes between the APT(+) and APT(-) groups in the ALL cohort or in the CAD and STROKE sub-cohorts. In the PAD subcohort, the HR [95% CI] for all-cause death in the APT(+) group increased (4.43 [1.05-18.71]; p=0.043). In the APT(+) group, the HR [95% CI] for any bleeding increased in the ALL cohort (1.28 [1.01-1.62]; p=0.044) and STROKE subcohort (1.42 [1.01-2.01]; p=0.047), and for major bleeding in the CAD subcohort (2.00 [1.01-3.93]; p=0.046). CONCLUSIONS: Rivaroxaban with APT did not reduce ischemic outcomes in patients with stable CAD or ischemic stroke; however, it did increase the risk of bleeding in patients with stable CAD or ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Kaikita et al. (2024) conducted a cohort in Non-valvular atrial fibrillation complicated by stable cardiovascular disease (n=2,030). Rivaroxaban plus antiplatelet therapy vs. Rivaroxaban alone was evaluated on Symptomatic stroke or systemic embolism (HR 1.07, 95% CI 0.63-1.81, p=0.795). In patients with non-valvular atrial fibrillation and stable cardiovascular disease, adding antiplatelet therapy to rivaroxaban did not reduce stroke or systemic embolism but increased bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: